BIOA

BioAge Labs, Inc. NASDAQ Listed Sep 26, 2024

Healthcare ·Biotechnology ·US · bioagelabs.com

$17.80

Mkt Cap $640.4M

52w Low $3.67 69.5% of range 52w High $24.00

50d MA $18.52 200d MA $12.08

P/E (TTM) -7.5x

EV/EBITDA -3.1x

P/B 2.2x

Debt/Equity 0.0x

ROE -29.6%

P/FCF -5.8x

RSI (14) —

ATR (14) —

Beta 1.83

50d MA $18.52

200d MA $12.08

Avg Volume 541.1K

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

CIK (SEC)

1709941

Phone

510 806 1445

1445A South 50th Street · Emeryville, CA 94804 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
May 8, 2026	BMO	—	—	—	17.82	-1.7%	+1.0%	—	—	—	—	—
May 7, 2026	BMO	—	—	—	18.46	-0.5%	-3.5%	—	—	—	—	—
Mar 24, 2026	BMO	-0.83	-0.72	+13.3%	16.11	+1.1%	+1.9%	+1.9%	+0.9%	+0.2%	-1.7%	—
Nov 6, 2025	BMO	-0.67	-0.56	+16.4%	7.47	-2.7%	-2.8%	-2.8%	+0.3%	+4.8%	+7.2%	—
Aug 6, 2025	BMO	-0.56	-0.60	-7.1%	4.33	+1.8%	-0.2%	-0.2%	+0.0%	+0.2%	+3.5%	—
May 6, 2025	BMO	-0.52	-0.36	+30.8%	3.95	+0.8%	+2.8%	+2.8%	+4.1%	+2.3%	+3.0%	—
Mar 20, 2025	BMO	-0.58	-1.97	-239.7%	4.38	-3.2%	+2.5%	+2.5%	+3.7%	-2.3%	-8.9%	—
Nov 7, 2024	BMO	-0.72	-6.70	-830.6%	20.62	+1.1%	+7.6%	+7.6%	+9.9%	-3.0%	-2.2%	—
Sep 26, 2024	BMO	—	-1.80	—	18.31	+5.4%	+14.7%	+14.7%	+13.6%	+10.6%	+7.8%	—
Mar 31, 2024	BMO	—	-1.74	—	—	—	—	—	—	—	—	—
Dec 31, 2023	BMO	—	-2.81	—	—	—	—	—	—	—	—	—
Sep 30, 2023	BMO	—	-1.96	—	—	—	—	—	—	—	—	—
Jun 30, 2023	BMO	—	-2.30	—	—	—	—	—	—	—	—	—
Mar 31, 2023	BMO	—	-1.48	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 10	Citigroup	Maintains	Buy → Buy	—	$19.73	$20.37	+3.2%	+6.3%	+1.7%	+0.8%	-5.1%	+9.2%
Feb 18	Jefferies	Upgrade	Hold → Buy	—	$19.63	$21.40	+9.0%	-0.2%	+2.6%	+4.5%	+8.8%	+9.8%
Dec 8	Morgan Stanley	Upgrade	Underweight → Equal Weight	—	$11.61	$11.35	-2.2%	+1.9%	+3.9%	+9.2%	+9.8%	+10.9%
Oct 29	Citigroup	Maintains	Buy → Buy	—	$7.89	$8.00	+1.4%	-2.7%	-2.0%	-4.1%	-6.0%	-5.3%
Oct 22	Citigroup	Upgrade	Neutral → Buy	—	$5.30	$5.69	+7.4%	+14.2%	+50.0%	+43.4%	+44.0%	+48.9%
Mar 24	Citigroup	Maintains	Neutral → Neutral	—	$4.49	$4.37	-2.7%	+1.1%	-4.7%	-11.1%	-13.6%	-14.9%
Dec 9	Citigroup	Downgrade	Buy → Neutral	—	$20.09	$5.65	-71.9%	-76.9%	-77.8%	-76.1%	-77.2%	-78.7%
Dec 9	Jefferies	Downgrade	Buy → Hold	—	$20.09	$5.65	-71.9%	-76.9%	-77.8%	-76.1%	-77.2%	-78.7%

Data updated apr 24, 2026 9:40pm · Source: massive.com